Article ID Journal Published Year Pages File Type
3976500 Brachytherapy 2015 7 Pages PDF
Abstract
WR, WR+ Cs-131, or SBRT are all excellent treatment options for patients with early stage non-small cell lung cancer that are not candidates for lobectomy. For high risk WRs, we favor use of Cesim-131 brachytherapy. Until a prospective randomized comparative study is done to evaluate the best treatment approach for early stage NSCLC, treatment selection should be based on a multidisciplinary team approach.
Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , , , , , ,